Zenas BioPharma Statistics
Total Valuation
Zenas BioPharma has a market cap or net worth of $1.77 billion. The enterprise value is $1.42 billion.
| Market Cap | 1.77B |
| Enterprise Value | 1.42B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, before market open.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenas BioPharma has 65.18 million shares outstanding. The number of shares has increased by 60.52% in one year.
| Current Share Class | 65.18M |
| Shares Outstanding | 65.18M |
| Shares Change (YoY) | +60.52% |
| Shares Change (QoQ) | +13.46% |
| Owned by Insiders (%) | 1.52% |
| Owned by Institutions (%) | 94.57% |
| Float | 45.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,776.72 |
| Forward PS | 34.45 |
| PB Ratio | 6.99 |
| P/TBV Ratio | 7.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,431.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.93, with a Debt / Equity ratio of 1.21.
| Current Ratio | 9.93 |
| Quick Ratio | 9.78 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.29 |
Financial Efficiency
Return on equity (ROE) is -199.04% and return on invested capital (ROIC) is -43.58%.
| Return on Equity (ROE) | -199.04% |
| Return on Assets (ROA) | -34.42% |
| Return on Invested Capital (ROIC) | -43.58% |
| Return on Capital Employed (ROCE) | -43.07% |
| Weighted Average Cost of Capital (WACC) | 0.41% |
| Revenue Per Employee | $5,988 |
| Profits Per Employee | -$2.90M |
| Employee Count | 167 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zenas BioPharma has paid $220,000 in taxes.
| Income Tax | 220,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.25% in the last 52 weeks. The beta is -0.88, so Zenas BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.88 |
| 52-Week Price Change | +5.25% |
| 50-Day Moving Average | 30.78 |
| 200-Day Moving Average | 25.03 |
| Relative Strength Index (RSI) | 42.00 |
| Average Volume (20 Days) | 765,096 |
Short Selling Information
The latest short interest is 11.94 million, so 18.32% of the outstanding shares have been sold short.
| Short Interest | 11.94M |
| Short Previous Month | 11.87M |
| Short % of Shares Out | 18.32% |
| Short % of Float | 26.52% |
| Short Ratio (days to cover) | 18.11 |
Income Statement
In the last 12 months, Zenas BioPharma had revenue of $1.00 million and -$484.38 million in losses. Loss per share was -$9.05.
| Revenue | 1.00M |
| Gross Profit | -212.47M |
| Operating Income | -273.90M |
| Pretax Income | -484.16M |
| Net Income | -484.38M |
| EBITDA | -273.87M |
| EBIT | -273.90M |
| Loss Per Share | -$9.05 |
Balance Sheet
The company has $643.13 million in cash and $297.86 million in debt, with a net cash position of $345.27 million or $5.30 per share.
| Cash & Cash Equivalents | 643.13M |
| Total Debt | 297.86M |
| Net Cash | 345.27M |
| Net Cash Per Share | $5.30 |
| Equity (Book Value) | 247.10M |
| Book Value Per Share | 3.90 |
| Working Capital | 587.98M |
Cash Flow
In the last 12 months, operating cash flow was -$225.97 million and capital expenditures -$2,000, giving a free cash flow of -$225.97 million.
| Operating Cash Flow | -225.97M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 31,000 |
| Net Borrowing | 296.60M |
| Free Cash Flow | -225.97M |
| FCF Per Share | -$3.47 |
Margins
| Gross Margin | n/a |
| Operating Margin | -27,390.10% |
| Pretax Margin | -48,416.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zenas BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -60.52% |
| Shareholder Yield | -60.52% |
| Earnings Yield | -27.26% |
| FCF Yield | -12.72% |
Analyst Forecast
The average price target for Zenas BioPharma is $47.88, which is 76.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.88 |
| Price Target Difference | 76.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 143.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenas BioPharma has an Altman Z-Score of -0.6 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.6 |
| Piotroski F-Score | 2 |